A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma. (14th August 2020)

• Record Type: Journal Article
• Authors: MacFarlane, James; Seong, Keat Cheah; Bisambar, Chad; Madhu, Basetti; Allinson, Kieren; Marker, Alison; Warren, Anne; Park, Soo‐Mi; Giger, Olivier; Challis, Benjamin G.; Maher, Eamonn R.; Casey, Ruth T.
• Is Part Of: Clinical endocrinology. Volume 93:Number 5(2020)
• Page Start: 528
• Page End: 538
• Publication Date: 2020-08-14
• Subjects: gastrointestinal stromal tumour -- immunohistochemistry -- paraganglioma -- phaeochromocytoma -- pituitary adenoma -- renal tumour -- succinate dehydrogenase; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.14289
• Languages: English
• ISSNs: 0300-0664

Abstract

Abstract: The citric acid cycle, also known as the Krebs cycle, plays an integral role in cellular metabolism and aerobic respiration. Mutations in genes encoding the citric acid cycle enzymes succinate dehydrogenase, fumarate hydratase and malate dehydrogenase all predispose to hereditary tumour syndromes. The succinate dehydrogenase enzyme complex (SDH) couples the oxidation of succinate to fumarate in the citric acid cycle and the reduction of ubiquinone to ubiquinol in the electron transport chain. A loss of function in the succinate dehydrogenase (SDH) enzyme complex is most commonly caused by an inherited mutation in one of the four SDHx genes ( SDHA, SDHB, SDHC and SDHD ). This mechanism was first implicated in familial phaeochromocytoma and paraganglioma. However, over the past two decades the spectrum of tumours associated with SDH deficiency has been extended to include gastrointestinal stromal tumours (GIST), renal cell carcinoma (RCC) and pituitary adenomas. The aim of this review is to describe the extended tumour spectrum associated with SDHx gene mutations and to consider how functional tests may help to establish the role of SDHx mutations in new or unexpected tumour phenotypes.